Personalised medicine is becoming a reality for a variety of diseases. A more individually targeted care will fundamentally change healthcare services and open new opportunities for the industry. Luxembourg has been at the field’s forefront since 2008, when it teamed with world-renowned research institutes to kick-start three projects as part of a new government-backed initiative: an international bio-banking infrastructure, a centre for systems biomedicine and research cooperation to validate biomarkers for lung cancer.
To support research and to make the country a global leader in incorporating personalised medicine into a national healthcare system, Luxembourg created the Personalised Medicine Consortium (PMC), which includes the IBBL (Integrated BioBank of Luxembourg), the Centre de Recherche Public – Santé (CRP – Santé) - now called Luxembourg Institute of Health - and the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg.
Since its creation in 2010, the consortium has supported research programmes in personalised healthcare, specifically in cancer, diabetes and Parkinson’s disease.
The country's appeal to the biomedical sector has further increased with the opening of the House of Biohealth, a unique hosting facility with office and lab spaces, for both established and start-up companies in the field of biotech, clean-tech and ICT.